drugset / Trial / NCT04910568
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
This Phase Ib, multicenter, open-label study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of cevostamab monotherapy, cevostamab plus pomalidomide and dexamethasone (Pd) or cevostamab plus daratumumab and dexamethasone (Dd) which will be administered to participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.
Timeline
- Start
- 2021-07-26
- Primary completion
- 2028-12-21
- Completion
- 2028-12-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cevostamab | Monoclonal antibody | — | Intravenous |
| Background | Daratumumab | Monoclonal antibody | — | Subcutaneous |
| Background | Dexamethasone | Small molecule | 20 mg | Intravenous |
| Background | Pomalidomide | Other / unclassified | — | Oral |
| Background | Tocilizumab | Monoclonal antibody | — | — |